KYMR vs. ARVN

In the year-to-date period, KYMR achieves a -6.98% return, which is significantly lower than ARVN's -4.17% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and Arvinas, Inc. (ARVN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current KYMR Sharpe Ratio is -0.05, which is higher than the ARVN Sharpe Ratio of -1.17. The chart below compares the historical Sharpe Ratios of KYMR and ARVN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither KYMR nor ARVN has paid dividends to shareholders.

The maximum KYMR drawdown since its inception was -87.51%, roughly equal to the maximum ARVN drawdown of -86.85%. Use the drawdown chart below to compare losses from any high point for KYMR and ARVN. For additional features, visit the drawdowns tool.

The current volatility for Kymera Therapeutics, Inc. (KYMR) is 12.79%, while Arvinas, Inc. (ARVN) has a volatility of 14.79%. This indicates that KYMR experiences smaller price fluctuations and is considered to be less risky than ARVN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Kymera Therapeutics, Inc. and Arvinas, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.